Browse ITGB2

Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Membrane raft Single-pass type I membrane protein
Domain PF08725 Integrin beta cytoplasmic domain
PF07965 Integrin beta tail domain
PF00362 Integrin beta chain VWA domain
PF17205 Integrin plexin domain
Function

Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins ITGAM/ITGB2 and ITGAX/ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin ITGAX/ITGB2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin ITGAM/ITGB2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin ITGAM/ITGB2 is also a receptor for factor X. Integrin ITGAD/ITGB2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992, PubMed:28807980). Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590). In association with alpha subunit ITGAM/CD11b, required for CD177-PRTN3-mediated activation of TNF primed neutrophils (PubMed:21193407).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002523 leukocyte migration involved in inflammatory response
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006809 nitric oxide biosynthetic process
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0007160 cell-matrix adhesion
GO:0007229 integrin-mediated signaling pathway
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0007568 aging
GO:0008360 regulation of cell shape
GO:0010631 epithelial cell migration
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022604 regulation of cell morphogenesis
GO:0030101 natural killer cell activation
GO:0030198 extracellular matrix organization
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031349 positive regulation of defense response
GO:0031589 cell-substrate adhesion
GO:0031623 receptor internalization
GO:0034113 heterotypic cell-cell adhesion
GO:0034142 toll-like receptor 4 signaling pathway
GO:0035987 endodermal cell differentiation
GO:0043062 extracellular structure organization
GO:0043112 receptor metabolic process
GO:0043113 receptor clustering
GO:0043542 endothelial cell migration
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045123 cellular extravasation
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0046209 nitric oxide metabolic process
GO:0048514 blood vessel morphogenesis
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050900 leukocyte migration
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051668 localization within membrane
GO:0055094 response to lipoprotein particle
GO:0055098 response to low-density lipoprotein particle
GO:0060326 cell chemotaxis
GO:0071402 cellular response to lipoprotein particle stimulus
GO:0071404 cellular response to low-density lipoprotein particle stimulus
GO:0071621 granulocyte chemotaxis
GO:0072593 reactive oxygen species metabolic process
GO:0072657 protein localization to membrane
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901342 regulation of vasculature development
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1904018 positive regulation of vasculature development
GO:1904407 positive regulation of nitric oxide metabolic process
GO:1990266 neutrophil migration
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0001948 glycoprotein binding
GO:0030369 ICAM-3 receptor activity
GO:0046982 protein heterodimerization activity
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0008305 integrin complex
GO:0034687 integrin alphaL-beta2 complex
GO:0043235 receptor complex
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04145 Phagosome
hsa04390 Hippo signaling pathway
hsa04514 Cell adhesion molecules (CAMs)
hsa04610 Complement and coagulation cascades
hsa04650 Natural killer cell mediated cytotoxicity
hsa04670 Leukocyte transendothelial migration
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-216083: Integrin cell surface interactions
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6798695: Neutrophil degranulation
R-HSA-449147: Signaling by Interleukins
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITGB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ITGB2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21647874Hepatocellular Carcinoma; Pancreatic CarcinomaPromote immunity (infiltration)The knockout of LFA-1 (also known as α(L) β(2) integrin) strongly suppressed recruitment of CD8(+) T cells whereas no significant differences of leukocyte adhesion and infiltration were found in ICAM-1(-/-) and Mac-1(-/-) mice. In contrast to acute inflammatory reaction, only LFA-1 controls recruitment of CD8(+) T-cells in both pancreatic and hepatocellular cancer, whereas ICAM-1 and Mac-1 are dispensable.
23325833leukemiaPromote immunityOur report identifies a novel cancer immune evasion mechanism whereby tumor cells induce Rho GTPase signaling defects in T cells that prevent appropriate LFA-1 activation and motility.
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITGB2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITGB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1750.683
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0350.989
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3310.857
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4470.439
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1650.942
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2250.68
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2950.606
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6180.737
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1080.959
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4850.472
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2010.716
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1310.499
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITGB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGB2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITGB2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITGB2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITGB2
Nameintegrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
Aliases MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITGB2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ITGB2.
ID Name Drug Type Targets #Targets
DB00641SimvastatinSmall MoleculeHMGCR, ITGAL, ITGB23